Comparison of effects of 3 mg drospirenone plus 20 μg ethinyl estradiol alone or combined with metformin or cyproterone acetate on classic metabolic cardiovascular.

Slides:

Advertisements

Similar presentations

Charles J. Glueck, M. D. , Joel Pranikoff, M. D. , Dawit Aregawi, M. D

Advertisements

Diastolic dysfunction and increased serum homocysteine concentrations may contribute to increased cardiovascular risk in patients with polycystic ovary.

Effects of metformin versus ethinyl-estradiol plus cyproterone acetate on ambulatory blood pressure monitoring and carotid intima media thickness in women.

Clinically significant and sustained weight loss is achievable in obese women with polycystic ovary syndrome followed in a regular medical practice Lysanne.

Short-term therapy with combination dipeptidyl peptidase-4 inhibitor saxagliptin/metformin extended release (XR) is superior to saxagliptin or metformin.

The effect of cinnamon extract on insulin resistance parameters in polycystic ovary syndrome: a pilot study Jeff G. Wang, M.D., Richard A. Anderson,

Opposing effects of dehydroepiandrosterone sulfate and free testosterone on metabolic phenotype in women with polycystic ovary syndrome Elisabeth Lerchbaum,

Comparison of hormonal and metabolic markers after a high-fat, Western meal versus a low-fat, high-fiber meal in women with polycystic ovary syndrome

Risk of obstructive sleep apnea in obese and nonobese women with polycystic ovary syndrome and healthy reproductively normal women Babak Mokhlesi, M.D.,

Fernando Zegers-Hochschild, M.D. Fertility and Sterility

Suppression and recovery of gonadotropin and steroid secretion by a gonadotropin- releasing hormone receptor antagonist in healthy women with normal ovulation.

Androgen and lipid profiles in adolescents with polycystic ovary syndrome who were treated with two forms of combined oral contraceptives George Mastorakos,

Kalliopi Kotsa, M. D. , Ph. D. , Maria P. Yavropoulou, M. D

Ovarian size and blood flow in women with polycystic ovary syndrome and their correlations with endocrine parameters Enrico Carmina, M.D., Francesco.

Possible metformin effect on adrenal androgens during pretreatment and IVF cycle in women with polycystic ovary syndrome Sigrun B. Kjøtrød, M.D., Arne.

Progression to impaired glucose tolerance or type 2 diabetes mellitus in polycystic ovary syndrome: a controlled follow-up study Cem Celik, M.D., Nicel.

Plasminogen activator inhibitor 1 and miscarriage after metformin treatment and laparoscopic ovarian drilling in patients with polycystic ovary syndrome

Metformin administration modulates and restores luteinizing hormone spontaneous episodic secretion and ovarian function in nonobese patients with polycystic.

The spectrum of androgen excess disorders

Vincenzo De Leo, M. D. , Valeria Scolaro, M. D

Serum insulin-like growth factor I (IGF-I) and IGF-binding protein 3 (IGFBP-3) in IVF patients with polycystic ovary syndrome: correlations with outcome

Insulin resistance in oligomenorrheic infertile women with non-polycystic ovary syndrome Shirei Ohgi, M.D., Koji Nakagawa, M.D., Ph.D., Rieko Kojima,

Risk of depression and other mental health disorders in women with polycystic ovary syndrome: a longitudinal study Angela Kerchner, B.A., Whitney Lester,

Robert A. Wild, M. D. , Manfredi Rizzo, M. D. , Sheri Clifton, Ph. D

Is the addition of metformin efficacious in the treatment of clomiphene citrate-resistant patients with polycystic ovary syndrome? A structured literature.

Obesity, weight loss, and the polycystic ovary syndrome: effect of treatment with diet and orlistat for 24 weeks on insulin resistance and androgen levels

Rebecca A. Feldman, M. D. , Kathleen O'Neill, M. D. , Samantha F

Letrozole versus combined metformin and clomiphene citrate for ovulation induction in clomiphene-resistant women with polycystic ovary syndrome: a randomized.

Pioglitazone reduces the adrenal androgen response to corticotropin-releasing factor without changes in ACTH release in hyperinsulinemic women with polycystic.

Clinical course of depression symptoms and predictors of enduring depression risk in women with polycystic ovary syndrome: Results of a longitudinal study

Epidemiology and Adverse Cardiovascular Disease (CVD) Risk Profile of Polycystic Ovarian Syndrome (PCOS): The Kaiser Permanente Polycystic Ovarian Syndrome.

Serum soluble leptin receptor levels and free leptin index in women with polycystic ovary syndrome: relationship to insulin resistance and androgens

Metabolic disturbances in non-obese women with polycystic ovary syndrome: a systematic review and meta-analysis Shiqin Zhu, M.D., Bingqian Zhang, M.D.,

Circulating and cellular adiponectin in polycystic ovary syndrome: relationship to glucose tolerance and insulin action Vanita Aroda, M.D., Theodore.

Hyperglycemia Stimulates Activation of Nuclear Factor κB (NFκB) in Mononuclear Cells (MNC) of Women With Polycystic Ovary Syndrome (PCOS) F. Gonzalez,

Role of insulin in the hyperandrogenemia of lean women with polycystic ovary syndrome and normal insulin sensitivity Jean-Patrice Baillargeon, M.D.,

Influence of adrenal hyperandrogenism on the clinical and metabolic phenotype of women with polycystic ovary syndrome Macarena Alpañés, M.D., Manuel.

Increased secretion of amylin in women with polycystic ovary syndrome

Effects of metformin and rosiglitazone, alone and in combination, in nonobese women with polycystic ovary syndrome and normal indices of insulin sensitivity

Fleur R. Cattrall, M. B. B. S. , Beverley J. Vollenhoven, M. B. B. S

Effect of the insulin sensitizers metformin and pioglitazone on endothelial function in young women with polycystic ovary syndrome: a prospective randomized.

Metformin reduces serum müllerian-inhibiting substance levels in women with polycystic ovary syndrome after protracted treatment Richard Fleming, Ph.D.,

Banu Ucar, M. D. , Volkan Noyan, M. D. , Osman Caglayan, M. D

Effects of treatment with testosterone alone or in combination with estrogen on insulin sensitivity in postmenopausal women Hong Zang, M.D., Kjell Carlström,

Cameron Gilbert, M. Sc. , Maria Valois, M. D. , FRCPC, Ph. D

Higher PDCD4 expression is associated with obesity, insulin resistance, lipid metabolism disorders, and granulosa cell apoptosis in polycystic ovary syndrome

Impact of laparoscopic ovarian drilling on anti-Müllerian hormone levels and ovarian stromal blood flow using three-dimensional power Doppler in women.

Pregnancy outcome in infertile patients with polycystic ovary syndrome who were treated with metformin Samuel S. Thatcher, M.D., Ph.D., Elizabeth M.

Dijana Hadžiomerović, M. D. , Bernhard Rabenbauer, M. D

Association of increased total antioxidant capacity and anovulation in nonobese infertile patients with clomiphene citrate–resistant polycystic ovary.

Fertility and Sterility: an evaluation

Paolo Moghetti, M.D. Fertility and Sterility

Metformin effects on ovarian ultrasound appearance and steroidogenic function in normal-weight normoinsulinemic women with polycystic ovary syndrome:

Comparison of clomiphene citrate, metformin, or the combination of both for first-line ovulation induction and achievement of pregnancy in 154 women with.

George Christodoulakos, M. D. , Irene Lambrinoudaki, M. D

Insulin resistance, obesity, inflammation, and depression in polycystic ovary syndrome: biobehavioral mechanisms and interventions Kristen Farrell, M.S.,

Current evaluation of amenorrhea

Tsan-Hon Liou, M. D. , Ph. D. , Jen-Hung Yang, M. D. , Ph. D

Effect of metformin on serum visfatin levels in patients with polycystic ovary syndrome Mesut Ozkaya, Assistant Professor, Erman Cakal, Specialist, Yusuf.

Clinical and laboratory characteristics of adolescents with both polycystic ovary disease and anorexia nervosa Orit Pinhas-Hamiel, M.D., Nurit Pilpel,

Effect of long-term naltrexone treatment on endocrine profile, clinical features, and insulin sensitivity in obese women with polycystic ovary syndrome

Endothelial function and insulin resistance in polycystic ovary syndrome: the effects of medical therapy Helena J. Teede, Ph.D., Caroline Meyer, Ph.D.,

Transforming growth factor-β1 and its receptor soluble endoglin are altered in polycystic ovary syndrome during controlled ovarian stimulation Reshef.

Adiponectin levels reflect the different phenotypes of polycystic ovary syndrome: study in normal weight, normoinsulinemic patients Artemis Karkanaki,

Decrease in adiponectin levels in women with polycystic ovary syndrome after an oral glucose tolerance test Dimitrios Panidis, M.D., Ph.D., Dimitrios.

Increased risk of depressive disorders in women with polycystic ovary syndrome Elizabeth Hollinrake, B.S., Alison Abreu, M.D., Michelle Maifeld, R.N.C.,

Androgen responses to adrenocorticotropic hormone infusion among individual women with polycystic ovary syndrome Kevin H. Maas, M.D., Ph.D., Sandy Chuan,

Relation of intra-abdominal fat distribution to metabolic disorders in nonobese patients with polycystic ovary syndrome Basak Yildirim, M.D., Nuran Sabir,

Adolescent girls with polycystic ovary syndrome showing different phenotypes have a different metabolic profile associated with increasing androgen levels

Advanced oxidation protein products are increased in women with polycystic ovary syndrome: relationship with traditional and nontraditional cardiovascular.

Presentation transcript:

Comparison of effects of 3 mg drospirenone plus 20 μg ethinyl estradiol alone or combined with metformin or cyproterone acetate on classic metabolic cardiovascular risk factors in nonobese women with polycystic ovary syndrome Franca Fruzzetti, M.D., Daria Perini, M.D., Veronica Lazzarini, M.D., Donatella Parrini, M.D., Marco Gambacciani, M.D., Andrea Riccardo Genazzani, M.D. Fertility and Sterility Volume 94, Issue 5, Pages 1793-1798 (October 2010) DOI: 10.1016/j.fertnstert.2009.10.016 Copyright © 2010 American Society for Reproductive Medicine Terms and Conditions

Figure 1 Changes in clinical characteristics and in the lipid profile of patients with PCOS submitted to treatment with DRP/EE20 alone or combined with metformin or CPA for 6 months. Data are expressed as means ± SD. The Wilcoxon test was performed to evaluate the differences in the response to each treatment in each group. P<.05 was considered statistically significant. aP<.01 vs. baseline value in the DRP/EE20 plus CPA group; bP<.05 vs. baseline value in the DRP/EE20 plus metformin group. Fertility and Sterility 2010 94, 1793-1798DOI: (10.1016/j.fertnstert.2009.10.016) Copyright © 2010 American Society for Reproductive Medicine Terms and Conditions

Figure 2 Changes in index of glucose tolerance and insulin sensitivity in patients with PCOS treated with DRP/EE20 alone or combined with metformin or CPA for 6 months. Data are expressed as means ± SD. The Wilcoxon test was performed to evaluate the differences in the response to each treatment in each group. P<.05 was considered statistically significant. aP<.01 vs. baseline value in the DRP/EE20 + CPA group; bP<.05 vs. baseline value in the DRP/EE20 + metformin group; cP<.005 vs. baseline value in the DRP/EE20 + CPA group; dP<.001 vs. baseline value in the DRP/EE20 + CPA group; eP<.05 vs. baseline value in the DRP/EE20 group; fP<.01 vs. baseline value in the DRP/EE20 group. AUC = AUC during OGTT. Fertility and Sterility 2010 94, 1793-1798DOI: (10.1016/j.fertnstert.2009.10.016) Copyright © 2010 American Society for Reproductive Medicine Terms and Conditions

Figure 3 Changes in serum androgen profile of patients with PCOS treated with DRP/EE20 alone or combined with metformin or CPA for 6 months. Data are expressed as means ± SD. The Wilcoxon test was performed to evaluate the differences in the response to each treatment in each group. P<.05 was considered statistically significant. aP<.01 vs. baseline value in the DRP/EE20 + CPA group; bP<.05 vs. baseline value in the DRP/EE20 + metformin group; cP<.005 vs. baseline value in the DRP/EE20 + CPA group; dP<.001 vs. baseline value in the DRP/EE20 + CPA group; eP<.05 vs. baseline value in the DRP/EE20 group; fP<.01 vs. baseline value in the DRP/EE20 group; gP<.001 vs. baseline value in the DRP/EE20 group; hP<.001 vs. baseline value in the DRP/EE20 + metformin group. Fertility and Sterility 2010 94, 1793-1798DOI: (10.1016/j.fertnstert.2009.10.016) Copyright © 2010 American Society for Reproductive Medicine Terms and Conditions